Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients

Journal of the American Society of Nephrology

Volumn 26, Issue 12, 2015, Pages 3114-3122

  Hricik, Donald E ^a   Formica, Richard N ^b   Nickerson, Peter ^c   Rush, David ^c   Fairchild, Robert L ^d   Poggio, Emilio D ^d   Gibson, Ian W ^c   Wiebe, Chris ^c   Tinckam, Kathryn ^e   Bunnapradist, Suphamai ^f   Samaniego Picota, Milagros ^g   Brennan, Daniel C ^h   Schröppel, Bernd ⁱ   Gaber, Osama ^j,k   Armstrong, Brian ^l   Ikle, David ^l   Diop, Helena ^m   Bridges, Nancy D ^m   Heeger, Peter S ⁱ  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j HOUSTON METHODIST HOSPITAL   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l RHO INC   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CXCL9 CHEMOKINE; DONOR SPECIFIC ANTIBODY; EPITOPE; GAMMA INTERFERON; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; CALCINEURIN INHIBITOR; CXCL9 PROTEIN, HUMAN; HLA DQ ANTIGEN;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FIBROSING ALVEOLITIS; GRAFT RECIPIENT; HUMAN; INFLAMMATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT WITHDRAWAL; URINALYSIS; AGED; ATROPHY; BLOOD; EARLY TERMINATION OF CLINICAL TRIAL; FIBROSIS; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; KIDNEY TUBULE; MIDDLE AGED; NEPHRITIS; PATHOLOGY; PROCEDURES; URINE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES; ATROPHY; CALCINEURIN INHIBITORS; CHEMOKINE CXCL9; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FIBROSIS; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; KIDNEY; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; MIDDLE AGED; NEPHRITIS; PROSPECTIVE STUDIES; TACROLIMUS; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84944092747     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014121234     Document Type: Article

References (31)

1. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, Leichtman AB: Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 6: 1111-1131, 2006
2. Menon MC, Murphy B: Maintenance immunosuppression in renal transplantation. Curr Opin Pharmacol 13: 662-671, 2013
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-612, 2000
4. Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4: 1289-1295, 2004
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite amarked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378-383, 2004
6. Ekberg H,Grinyó J, Nashan B, VanrenterghemY, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 7: 560-570, 2007
7. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation.NEngl JMed 357: 2562-2575, 2007
8. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
9. Abramowicz D, Del Carmen RialM, Vitko S, del CastilloD,ManasD, Lao M, Gafner N, Wijngaard P; Cyclosporine Withdrawal Study Group: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 16: 2234-2240, 2005
10. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74: 1560-1567, 2002
11. TanHP,Donaldson J, Basu A, UnruhM, Randhawa P, Sharma V,Morgan C, McCauley J, Wu C, Shah N, Zeevi A, Shapiro R: Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 9: 355-366, 2009
12. Roodnat JI, Hilbrands LB, Hené RJ, de Sévaux RG, Smak Gregoor PJ, Kal-van Gestel JA, Konijn C, van Zuilen A, van Gelder T, Hoitsma AJ, Weimar W: 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation 98: 47-53, 2014
13. Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW: Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13: 536-543, 2002
14. Smak Gregoor PJ, de Sévaux RG, Ligtenberg G, Hoitsma AJ, Hené RJ, Weimar W, Hilbrands LB, van Gelder T: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J AmSoc Nephrol 13: 1365-1373, 2002
15. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, KuypersD, Stuart F, KhannaA,Navarro M,Nashan B:Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71: 1282-1287, 2001
16. Asberg A, Apeland T, Reisaeter AV, Foss A, Leivestad T, Heldal K, Thorud LO, Eriksen BO, Hartmann A; NILS Study Group: Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results froman aborted trial. Clin Transplant 27: E151-E156, 2013
17. Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, Goebel J,Gibson IW, Fairchild RL, RiggsM, Spain K, IkleD, Bridges ND, Heeger PS; CTOT-01 consortium: Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 13: 2634-2644, 2013
18. Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, Knechtle SJ, Friedewald J, Becker YT, Sharma VK, Williams NM, Chang CS, Hoang C,Muthukumar T, August P, Keslar KS, Fairchild RL, Hricik DE, Heeger PS, Han L, Liu J, Riggs M, Ikle DN, Bridges ND, Shaked A; Clinical Trials in Organ Transplantation 04 (CTOT-04) Study Investigators: Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 369: 20-31, 2013
19. Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, Goldberg A, Storsley LJ, Gibson IW, Rush DN, Nickerson PW: Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 13: 3114-3122, 2013
20. Augustine JJ, SiuDS, ClementeMJ, Schulak JA, Heeger PS, Hricik DE: Pretransplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 5: 1971-1975, 2005
21. Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA, Tary-Lehmann M: Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 163: 2267-2275, 1999
22. Hricik DE, Rodriguez V, Riley J, Bryan K, Tary-Lehmann M, Greenspan N, Dejelo C, Schulak JA, Heeger PS: Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients.AmJ Transplant 3: 878-884, 2003
23. Hricik DE, Poggio ED, Woodside KJ, Sarabu N, Sanchez EQ, Schulak JA, Padiyar A, Heeger PS, Augustine JJ: Effects of cellular sensitization and donor age on acute rejection and graft function after deceaseddonor kidney transplantation. Transplantation 95: 1254-1258, 2013
24. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW: Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12: 1157-1167, 2012
25. Kasiske BL, Heim-Duthoy K, Ma JZ: Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 269: 395-400, 1993
26. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL; Immune Tolerance Network ST507 Study Group: Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120: 1836-1847, 2010
27. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI: Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848-1861, 2010
28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
29. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI: Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75: 43-49, 2003
30. Ashoor I, Najafian N, Korin Y, Reed EF, Mohanakumar T, Ikle D, Heeger PS, Lin M: Standardization and cross validation of alloreactive IFNg ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 13: 1871-1879, 2013
31. Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG; Modification of Diet in Renal Disease (MDRD) Study Group: Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int Suppl 27: S73-S80, 1989